🔎 Trials Near Me

Početna › Prekomjerna tjelesna masa › Utah

Kliničke studije za Prekomjerna tjelesna masa u državi Utah

22 studija za Prekomjerna tjelesna masa traži sudionike na lokacijama u državi Utah.

Gradovi u državi Utah

Službeni tekst studije (engleski)

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

  • AMR Clinical, Layton
U tijeku regrutacijaFaza 3
Od 8 do 18 godina · Oba spola · Ažurirano 30. ruj 2026. · NCT07253285

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

  • AMR Clinical, South Jordan
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT07837973

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • Velocity Clinical Research, Salt Lake City, West Jordan
U tijeku regrutacijaFaza 3
Od 6 do 17 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06672549

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • Ogden Clinic - Canyon View, Ogden
  • Diabetes & Endocrine Treatment Specialists, Sandy City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07282600

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  • Boeson Research, Provo
  • Velocity Clinical Research - Salt Lake City, West Jordan
U tijeku regrutacijaFaza 3
Od 45 do 99 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT07037433

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  • AMR Clinical, South Jordan
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07353931

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  • AURORA-1 Clinical Site, Salt Lake City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Salt Lake City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743450

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  • George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT07351045

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

  • ACCOMPLISH-2 Research Site, Salt Lake City
U tijeku regrutacijaFaza 3Zdravi dobrovoljci dobrodošli
Od 18 do 79 godina · Oba spola · Ažurirano 11. ruj 2026. · NCT07654374

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

  • Kalo Clinical Research, West Valley City
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT07215559

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Pleasant View
  • Kailera Clinical Site, Salt Lake City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Pantheon Clinical Research, Bountiful
  • Alliance for Multispecialty Research Layton Research Center, Layton
  • Chrysalis Clinical Research, LLC, St. George
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  • Kailera Clinical Site, Salt Lake City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284875

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

  • ICON Early Phase Services, LLC, Salt Lake City
U tijeku regrutacijaFaza 1Zdravi dobrovoljci dobrodošli
Od 18 do 65 godina · Oba spola · Ažurirano 1. ruj 2026. · NCT07654972

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Salt Lake City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT07784725

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Sandy City
  • ACCOMPLISH-1 Research Site, St. George
U tijeku regrutacijaFaza 3
Od 18 do 79 godina · Oba spola · Ažurirano 10. kol 2026. · NCT07654361

Circadian Intervention to Improve Cardiometabolic Health

  • College of Health Research Complex--University of Utah, Salt Lake City
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 do 45 godina · Oba spola · Ažurirano 5. kol 2026. · NCT05943626

Effect of Sleep Extension on Ceramides in People With Overweight and Obesity

  • College of Health Research Complex--University of Utah, Salt Lake City
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 do 45 godina · Oba spola · Ažurirano 5. kol 2026. · NCT06180837

Testing a Tailored Approach to Long-Term Weight Loss Success

  • University of Utah, Salt Lake City
U tijeku regrutacijaZdravi dobrovoljci dobrodošli
Od 18 do 65 godina · Oba spola · Ažurirano 11. svi 2026. · NCT07577765

The Acute T-Rex (Timing of Resistance Exercise) Study

  • University of Utah HPER E Buildling, Salt Lake City
U tijeku regrutacija
Od 50 do 74 godina · Oba spola · Ažurirano 3. tra 2025. · NCT06366399

Iz ClinicalTrials.gov, podaci preuzeti 4. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.